Literature DB >> 30228186

K-Ras Lys-42 is crucial for its signaling, cell migration, and invasion.

Byeong Hyeok Choi1, Mark R Philips2, Yuan Chen3, Lou Lu4, Wei Dai5,6.   

Abstract

Ras proteins participate in multiple signal cascades, regulating crucial cellular processes, including cell survival, proliferation, and differentiation. We have previously reported that Ras proteins are modified by sumoylation and that Lys-42 plays an important role in mediating the modification. In the current study, we further investigated the role of Lys-42 in regulating cellular activities of K-Ras. Inducible expression of K-RasV12 led to the activation of downstream components, including c-RAF, MEK1, and extracellular signal-regulated kinases (ERKs), whereas expression of K-RasV12/R42 mutant compromised the activation of the RAF/MEK/ERK signaling axis. Expression of K-RasV12/R42 also led to reduced phosphorylation of several other protein kinases, including c-Jun N-terminal kinase (JNK), Chk2, and focal adhesion kinase (FAK). Significantly, K-RasV12/R42 expression inhibited cellular migration and invasion in vitro in multiple cell lines, including transformed pancreatic cells. Given that K-Ras plays a crucial role in mediating oncogenesis in the pancreas, we treated transformed pancreatic cells of both BxPC-3 and MiaPaCa-2 with 2-D08, a small ubiquitin-like modifier (SUMO) E2 inhibitor. Treatment with the compound inhibited cell migration in a concentration-dependent manner, which was correlated with a reduced level of K-Ras sumoylation. Moreover, 2-D08 suppressed expression of ZEB1 (a mesenchymal cell marker) with concomitant induction of ZO-1 (an epithelial cell marker). Combined, our studies strongly suggest that posttranslational modification(s), including sumoylation mediated by Lys-42, plays a crucial role in K-Ras activities in vivo.
© 2018 Choi et al.

Entities:  

Keywords:  K-Ras; Ras protein; cell invasion; cell migration; domain structure; lysine residue; posttranslational modification (PTM); signaling; sumoylation; transformation

Mesh:

Substances:

Year:  2018        PMID: 30228186      PMCID: PMC6231119          DOI: 10.1074/jbc.RA118.003723

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Authors:  Reuben J Shaw; Lewis C Cantley
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

Review 2.  Oncogene-induced senescence pathways weave an intricate tapestry.

Authors:  Paul Yaswen; Judith Campisi
Journal:  Cell       Date:  2007-01-26       Impact factor: 41.582

3.  Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras.

Authors:  P Rodriguez-Viciana; P H Warne; A Khwaja; B M Marte; D Pappin; P Das; M D Waterfield; A Ridley; J Downward
Journal:  Cell       Date:  1997-05-02       Impact factor: 41.582

4.  K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif.

Authors:  Frederick D Tsai; Mathew S Lopes; Mo Zhou; Helen Court; Odis Ponce; James J Fiordalisi; Jessica J Gierut; Adrienne D Cox; Kevin M Haigis; Mark R Philips
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-05       Impact factor: 11.205

Review 5.  The EMT regulator slug and lung carcinogenesis.

Authors:  Jin-Yuan Shih; Pan-Chyr Yang
Journal:  Carcinogenesis       Date:  2011-06-10       Impact factor: 4.944

6.  Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9.

Authors:  Bing Yu; Stephen Swatkoski; Alesia Holly; Liam C Lee; Valentin Giroux; Chih-Shia Lee; Dennis Hsu; Jordan L Smith; Garmen Yuen; Junqiu Yue; David K Ann; R Mark Simpson; Chad J Creighton; William D Figg; Marjan Gucek; Ji Luo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-24       Impact factor: 11.205

7.  Phosphorylated K-Ras limits cell survival by blocking Bcl-xL sensitization of inositol trisphosphate receptors.

Authors:  Pamela J Sung; Frederick D Tsai; Horia Vais; Helen Court; Jun Yang; Nicole Fehrenbacher; J Kevin Foskett; Mark R Philips
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

8.  Origin and function of myofibroblasts in kidney fibrosis.

Authors:  Valerie S LeBleu; Gangadhar Taduri; Joyce O'Connell; Yingqi Teng; Vesselina G Cooke; Craig Woda; Hikaru Sugimoto; Raghu Kalluri
Journal:  Nat Med       Date:  2013-06-30       Impact factor: 53.440

9.  Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.

Authors:  Ana Herrero; Adán Pinto; Paula Colón-Bolea; Berta Casar; Mary Jones; Lorena Agudo-Ibáñez; Rebeca Vidal; Stephan P Tenbaum; Paolo Nuciforo; Elsa M Valdizán; Zoltan Horvath; Laszlo Orfi; Antonio Pineda-Lucena; Emilie Bony; Gyorgy Keri; Germán Rivas; Angel Pazos; Rafael Gozalbes; Héctor G Palmer; Adam Hurlstone; Piero Crespo
Journal:  Cancer Cell       Date:  2015-08-10       Impact factor: 31.743

Review 10.  Ras acylation, compartmentalization and signaling nanoclusters (Review).

Authors:  Yoav I Henis; John F Hancock; Ian A Prior
Journal:  Mol Membr Biol       Date:  2008-12-27       Impact factor: 2.857

View more
  12 in total

Review 1.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

Review 2.  Ubiquitin and Ubiquitin-like Proteins in Cancer, Neurodegenerative Disorders, and Heart Diseases.

Authors:  Jin-Taek Hwang; Ahyoung Lee; Changwon Kho
Journal:  Int J Mol Sci       Date:  2022-05-02       Impact factor: 6.208

3.  Oncogenic Kras-Mediated Cytokine CCL15 Regulates Pancreatic Cancer Cell Migration and Invasion through ROS.

Authors:  Justin K Messex; Kiyah L A Adams; William G Hawkins; David DeNardo; Nabeel Bardeesy; Daniel D Billadeau; Geou-Yarh Liou
Journal:  Cancers (Basel)       Date:  2022-04-26       Impact factor: 6.575

Review 4.  Post-translational modification of RAS proteins.

Authors:  Sharon L Campbell; Mark R Philips
Journal:  Curr Opin Struct Biol       Date:  2021-08-06       Impact factor: 6.809

5.  Identification of Radil as a Ras binding partner and putative activator.

Authors:  Byeong Hyeok Choi; Ziyue Kou; Tania Marlyn Colon; Chih-Hong Chen; Yuan Chen; Wei Dai
Journal:  J Biol Chem       Date:  2021-01-20       Impact factor: 5.157

Review 6.  Post-translational modification of KRAS: potential targets for cancer therapy.

Authors:  Wei-Hua Wang; Tao Yuan; Mei-Jia Qian; Fang-Jie Yan; Liu Yang; Qiao-Jun He; Bo Yang; Jin-Jian Lu; Hong Zhu
Journal:  Acta Pharmacol Sin       Date:  2020-10-21       Impact factor: 7.169

Review 7.  SUMOylation in development and neurodegeneration.

Authors:  Tak-Yu Yau; Oscar Molina; Albert J Courey
Journal:  Development       Date:  2020-03-18       Impact factor: 6.862

8.  2-D08 treatment regulates C2C12 myoblast proliferation and differentiation via the Erk1/2 and proteasome signaling pathways.

Authors:  Hyunju Liu; Su-Mi Lee; Hosouk Joung
Journal:  J Muscle Res Cell Motil       Date:  2021-06-17       Impact factor: 2.698

Review 9.  Novel insights into the impact of the SUMOylation pathway in hematological malignancies (Review).

Authors:  Ling Wang; Jinjun Qian; Ye Yang; Chunyan Gu
Journal:  Int J Oncol       Date:  2021-08-09       Impact factor: 5.650

Review 10.  SUMOylation of synaptic and synapse-associated proteins: An update.

Authors:  Jeremy M Henley; Richard Seager; Yasuko Nakamura; Karolina Talandyte; Jithin Nair; Kevin A Wilkinson
Journal:  J Neurochem       Date:  2020-07-05       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.